Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOSEMITE study of faricimab versus aflibercept in diabetic macular edema
MOH_2018-07-26_002481Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of faricimab and aflibercept in diabetic macular edema (DME) (3 arms), sponsored by Roche. Started Nov 2018; status: completed.
02
Drugs
faricimabaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2018-07-26_002481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-26_002481.